Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9939056 | 0.94 | MAPT (0.51) | TSHRFOLH1HDAC3MAPK1ADRA1A | |
| SCHEMBL6573770 | 0.90 | TSHR (0.46) | TSHRFOLH1HDAC3MAPK1ADRA1A | |
| SCHEMBL5472579 | 0.90 | TSHR (0.55) | TSHRFOLH1HDAC3MAPK1ADRA1A | |
| SCHEMBL2365443 | 0.86 | TSHR (0.57) | TSHRCETP | |
| SCHEMBL6576055 | 0.85 | LMNA (0.48) | TSHRFOLH1CETP | |
| SCHEMBL26985923 | 0.83 | TSHR (0.55) | TSHRCETP | |
| SCHEMBL23067163 | 0.83 | TSHR (0.44) | TSHRFOLH1MAPK1CETP | |
| SCHEMBL8790528 | 0.82 | TSHR (0.53) | TSHRSMN1; SMN2CETPHTT | |
| SCHEMBL16394878 | 0.81 | TSHR (0.52) | TSHRCETP | |
| SCHEMBL21121992 | 0.81 | TSHR (0.51) | TSHRSMN1; SMN2CETPHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4714961-A2 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4209483-B1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025080879-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4209483-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116283647-A | Prodrug modulators that integrate stress pathways | 卡里科生命科学有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113423685-B | Prodrug modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-11-29 | — | — | CN | disclosed |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220251123-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2022-08-11 | — | — | US | disclosed |
| WO-2012081978-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012081978-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2012-06-21 | — | — | WO | disclosed |
| US-20040249152-A1 | Method for the production of cna | NANOGEN RECOGNOMICS GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1427710-A2 | METHOD FOR THE PRODUCTION OF CNA | Nanogen Recognomics GmbH (DE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003016561-A2 | METHOD FOR THE PRODUCTION OF CNA | NANOGEN RECOGNOMICS GMBH (DE) | 2003-02-27 | — | — | WO | disclosed |
| EP-0558959-B1 | Phosphonooxy and carbonate derivatives of taxol | BRISTOL MYERS SQUIBB CO (US) | 1997-04-16 | — | — | EP | disclosed |
| US-H1487-H | Antitumor agents; treatment of ovarian, breast and other cancers | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-09-05 | — | — | US | disclosed |
| US-5272171-A | Phosphonooxy and carbonate derivatives of taxol | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0569281-A1 | Benzoate derivatives of taxol | Bristol-Myers Squibb Company (US) | 1993-11-10 | — | — | EP | disclosed |
| EP-0558959-A1 | Phosphonooxy and carbonate derivatives of taxol | Bristol-Myers Squibb Company (US) | 1993-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | TSHR 4706/4885FOLH1 206/4885HDAC3 447/4885 |
| US-20220251123-A1 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | TSHR 2909/4885FOLH1 3778/4885HDAC3 224/4885 |
| US-20040249152-A1 | Method for the production of cna | RNGTT, COASY, CNOT7 | TSHR 3677/4885FOLH1 4321/4885HDAC3 2500/4885 |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | TSHR 3245/4885FOLH1 342/4885HDAC3 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.